IRVINE, Calif., Aug. 11 /PRNewswire-FirstCall/ -- CalbaTech, Inc. , an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, announced today that its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland (http://www.kdmedical.com), a leading manufacturer of bacterial and yeast growth media, microbiological biological buffers and reagents, is acquiring a new facility that has two validated, Class 100 Clean Rooms for additional manufacture of products.
K-D Medical is a primary vendor to the National Institutes of Health (NIH) and currently sells products to every major pharmaceutical company in the U.S. K-D Medical's founder, John Powers, said the new Clean Rooms, plus a complete quality control laboratory, will allow the Company to manufacture a higher quality product as well as expand the current custom product offering, better serving the needs of both existing and new customers. "This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Mr. Powers said.
"These new facilities allow K-D Medical to open new manufacturing and Clean Room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," said James DeOlden, Chairman and CEO, CalbaTech. "We are very bullish on our subsidiary's future."
ABOUT K-D MEDICAL
K-D Medical, located in the heart of the Maryland Biotech Corridor, is one of the nation's leading manufacturers of microbiological culture media and other research reagents. K-D Medical's products are used in drug discovery, microbiology labs and biopharmaceutical production. The private Company is headquartered in Columbia, Maryland.
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. It is concentrating on acquiring, incubating and developing life science based companies that are developing current and future generation products and technologies, both in the United States and in the United Kingdom. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that intend to contribute innovation in areas of biological discovery.
Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.